Dr. Feehery joined Certara in June, 2019 as CEO. Dr. Feehery joins Certara from DuPont, where he served since 2013 as president of DuPont Industrial Biosciences, a $2.2 billion global biotechnology business that experienced significant growth and profitability under his leadership. In that role, he had full P&L responsibility for 3,000 people, including 500 R&D staff, 20 manufacturing plants, and worldwide marketing and sales across multiple markets. He joined DuPont in 2002 and served in a series of management roles in high-growth businesses, and he also has prior experience in venture capital and as a consultant for the Boston Consulting Group.
Dr. Feehery also serves as a board member for West Pharmaceutical Services (NYSE: WST), a manufacturer of packaging components and delivery systems for pharmaceutical, biotech and medical device companies.
Dr. Feehery holds both a Ph.D. in chemical engineering and an MBA from MIT. He was a Churchill Scholar at Cambridge University and received his BSE in chemical engineering from the University of Pennsylvania. His doctorate, awarded while he was the recipient of a National Science Foundation Fellowship, involved developing software and mathematical methods for modeling complex systems.